Home \ Research \ Scientific publications \


VanA-mediated high level glycopeptide resistance in MRSA

Investigation published in The Lancet Infectious Diseases

February 1st, 2003

We recently encountered what many consider to be the most important
event of the past 20 years in bacterial antibiotic resistance—namely, the isolation in hospitals in Michigan (July 2002) and Pennsylvania (October 2002) of two distinct meticillinresistant Staphylococcus aureus (MRSA)that are also resistant to high concentrations of vancomycin




Gonzalez-Zorn B. and Courvalin P.




See this article
VanA-mediated high level glycopeptide resistance in MRSA

See it on NLM PubMed
VanA-mediated high level glycopeptide resistance in MRSA



Participants:

Universidad ComplutenseDepartamento de Sanidad Animal. Facultad de Veterinaria. Universidad Complutense (UCM).

Universidad ComplutenseServicio de Zoonosis de Transmisión Alimentaria y Resistencia a Antimicrobianos (ZTA). Centro de Vigilancia Sanitaria Veterinaria (VISAVET). Universidad Complutense (UCM).

Institut PasteurInstitut Pasteur.







FACTOR YEAR Q
10.788 2004

NLMID: 101130150

PMID: 12560187

ISSN: 1473-3099



TITLE: VanA-mediated high level glycopeptide resistance in MRSA


JOURNAL: Lancet Infect Dis


NUMERACIÓN: 3(2):67-8


AÑO: 2003


PUBLISHER: Elsevier Science


AUTHORS: Gonzalez-Zorn B. and Courvalin P.


Bruno González Zorn

DOI: https://doi.org/10.1016/S1473-3099(03)00510-3


CITE THIS PUBLICATION:

Gonzalez-Zorn B. and Courvalin P. VanA-mediated high level glycopeptide resistance in MRSA. The Lancet Infectious Diseases. 3(2):67-8. 2003. (A). ISSN: 1473-3099. DOI: 10.1016/S1473-3099(03)00510-3


UNITS: